Petras Michael B. Jr. sold $15.7M of SHC (indirect holdings)

Petras Michael B. Jr. (Executive Chairman) sold 850,000 indirectly-held shares of Sotera Health Co (SHC) at $18.50 ($15.73M total) on 2026-08-17.

Original reporting
SEC EDGAR · Petras Michael B. Jr.
Published Aug 19, 2026, 8:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 8:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SHC
Bearish
medium confidence
Mentioned
$SHC
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SHCBearishLow
01

Why it matters

The sale reduces insider ownership, which may be interpreted as a bearish sign.

02

Market read

Direct impact on SHC stock; limited broader market effect.

03

What to watch

No accompanying earnings or guidance change; market may discount the sell.

Relevance 7/10Novelty 6/10Timing: post-market 2026-08-17

Background

Form 4 filing discloses insider transactions to the SEC.

Company-level read

Ticker impact

$SHCBearishMedium confidence
Context

Executive Chairman sold 850,000 shares for $15.7M, reducing his stake to 3.97M shares.

Expected impact

Potential modest decline in SHC price over the next few days.

Evidence & confidence

Significant insider sell by a top executive often signals lack of confidence, but no other catalyst is present.

Market effects

Minimal impact on healthcare services sector.

US market only.

Low

Counterpoint

Insider sell could be routine diversification, not a negative signal.

Key entities

  • Petras Michael B. Jr.

    Reported insider sale of SHC shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

MedAI 8/10

Sotera Health Company Q3 2026 Earnings Call Summary

Sotera Health reported Q3 2026 earnings, with Sterigenics and Nelson Labs driving performance. Nordion saw revenue decline due to cobalt-60 timing. Management noted European market softness. Guidance reaffirmed, with flat Q4 Sterigenics revenue and reduced 2027 CapEx. Nelson Labs' growth expected to moderate. Net leverage improved to 2.9x, leading to a credit rating upgrade. Litigation and FX headwinds noted.

$SHCHighAI 8/10

Sotera Health (SHC) Q3 2026 Earnings Call Transcript

Sotera Health (SHC) reported Q3 2026 revenue growth of 4.4% to $325M and adjusted EBITDA growth of 4% to $171M. Sterigenics grew 8.2%, Nelson Labs 9.2%, and Nordion declined 11.5%. The company reaffirmed its 2026 revenue and adjusted EBITDA outlook, expecting 5.25-6.75% and 5.75-7.25% growth, respectively. Adjusted EBITDA margins expanded sequentially by 100 basis points to 52.5%.

$SHCHighAI 8/10

Why is Sotera Health stock sliding today?

Sotera Health (SHC) shares fell 9.5% despite Q3 2026 earnings beat (EPS $0.29, revenue $324.9M) due to cautious guidance. Revenue declined 12% in the Nordion segment. JPMorgan downgraded to Underweight with a $17 target, and insiders sold 1.29M shares. The S&P 500 and Nasdaq rose, but Sotera's decline was company-specific.

$SHCMed

What Sotera Health (SHC) Said on Its Q3 Earnings Call

Sotera Health (SHC) reported Q3 earnings, noting softness in the European medical-device market. Sterigenics expects 6% constant-currency growth in Q4, while Nelson Labs saw 8.8% revenue growth. Nordion revenue fell 12.4% due to shipment timing. The company reaffirmed its 2026 outlook for 5.25% to 6.75% revenue growth and maintained its adjusted EBITDA forecast.